ArticleSurgical endoscopy2026
New access to intraluminal gastric pathologies: the SP da Vinci transgastric approach.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical management of gastric submucosal tumors in anatomically challenging sites such as the gastroesophageal junction (GEJ), fundus, or proximal lesser curvature remains technically demanding. The da Vinci single-port (SP) robotic platform may provide a minimally invasive, organ-preserving alternative by enabling stable endoluminal access and precise dissection.
methodsWe conducted a case series of five patients who underwent SP robot-assisted transgastric resections for circumscribed gastric pathologies between May and August 2025. Patient demographics, tumor characteristics, operative details, pathology, and short-term outcomes were analyzed.
resultsTwo patients presented with gastric metastases from malignant melanoma, one with a neuroendocrine tumor (NET), one with a gastrointestinal stromal tumor (GIST), and one with a leiomyoma. All lesions were located in anatomically challenging areas and ranged in size from < 1 cm to 5.5 cm. Four patients underwent submucosal dissection, and one required full-thickness resection. Operative times ranged from 66 to 134 min. Median console time was 38 min. No bleeding, conversion, tumor rupture, or spillage occurred. Patients were discharged between postoperative day (POD)-3 and POD-7, with no reoperations, morbidity, or 30-day mortality. Histopathology confirmed R0 resection of one GIST and both melanoma metastases; the NET G2 had positive margins but very low proliferative activity (Ki-67 < 0.1%).
conclusionsDa Vinci SP robot-assisted transgastric resection is a feasible and safe organ-preserving technique for GEJ and gastric tumors. The platform offers great exposure, stable endoluminal access, and three arms for dissection. This technique complements established endoscopic and laparoscopic procedures. The presented method could also be combined with extraluminal lymphadenectomy. Larger studies with long-term follow-up will define optimal indications and the role of this innovative approach within minimally invasive gastric surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.